Within the secondary analysis, the much less conservative but clinically meaningful criterion of secure response (described as being a fifty% or more reduction in MADRS from baseline for two months) was used. With the patients who attained secure response, twenty five.8% during the esketamine group and 57.6% within the placebo https://richardh666gwk4.blogrelation.com/profile